Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects

Science Translational Medicine

Volumn 5, Issue 171, 2013, Pages

  Allen, Joshua E ^a,b   Krigsfeld, Gabriel ^b   Mayes, Patrick A ^b   Patel, Luv ^b   Dicker, David T ^a,b   Patel, Akshal S ^a,c   Dolloff, Nathan G ^a,b   Messaris, Evangelos ^d   Scata, Kimberly A ^a,b   Wang, Wenge ^a   Zhou, Jun Ying ^e   Wu, Gen Sheng ^e   El Deiry, Wafik S ^a,b,f  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

^f AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CASPASE 8; DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND INDUCING COMPOUND 10; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CELL NUCLEUS TRANSPLANTATION; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME METABOLISM; FEMALE; GENE INDUCTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND GENE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BYSTANDER EFFECT; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MICE; MODELS, BIOLOGICAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874051647     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004828     Document Type: Article

References (44)

1. G. Pan, K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, V. M. Dixit, The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113 (1997).
2. G. Pan, J. Ni, Y. F. Wei, G. Yu, R. Gentz, V. M. Dixit, An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818 (1997).
3. G. S. Wu, T. F. Burns, E. R. McDonald III, W. Jiang, R. Meng, I. D. Krantz, G. Kao, D. D. Gan, J. Y Zhou, R. Muschel, S. R. Hamilton, N. B. Spinner, S. Markowitz, G. Wu, W. S. El-Deiry, KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17, 141-143 (1997).
4. A. Ashkenazi, Targeting death and decoy receptors of the tumour-necrosis factor super-family. Nat. Rev. Cancer 2, 420-430 (2002).
5. F. A. Greco, P. Bonomi, J. Crawford, K. Kelly, Y. Oh, W. Halpern, L. Lo, G. Gallant, J. Klein, Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61, 82-90 (2008).
6. D. R. Camidge, R. S. Herbst, M. S. Gordon, S. G. Eckhardt, R. Kurzrock, B. Durbin, J. Ing, T. M. Tohnya, J. Sager, A. Ashkenazi, G. Bray, D. Mendelson, A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin. Cancer Res. 16, 1256-1263 (2010).
7. T. Trarbach, M. Moehler, V. Heinemann, C H. Köhne, M. Przyborek, C Schulz, V. Sneller, G. Gallant, S. Kanzler, Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer 102, 506-512 (2010).
8. C H. Mom, J. Verweij, C N. Oldenhuis, J. A. Gietema, N. L. Fox, R. Miceli, F. A. Eskens, W. J. Loos, E. G. de Vries, S. Sleijfer, Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study. Clin. Cancer Res. 15, 5584-5590 (2009).
9. S. Leong, R. B. Cohen, D. L. Gustafson, C. J. Langer, D. R. Camidge, K. Padavic, L. Gore, M. Smith, L. Q. Chow, M. von Mehren, C. O'Bryant, S. Hariharan, S. Diab, N. L. Fox, R. Miceli, S. G. Eckhardt, Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase I and pharmacokinetic study. J. Clin. Oncol. 27, 4413-4421 (2009).
10. R. Plummer, G. Attard, S. Pacey, L Li, A. Razak, R. Perrett, M. Barrett, I. Judson, S. Kaye, N. L Fox, W. Halpern, A. Corey, H. Calvert, J. de Bono, Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13, 6187-6194 (2007).
11. A. W. Tolcher, M. Mita, N. J. Meropol, M. von Mehren, A. Patnaik, K. Padavic, M. Hill, T. Mays, T. McCoy, N. L. Fox, W. Halpern, A. Corey, R. B. Cohen, Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25, 1390-1395 (2007).
12. E. Bremer, W. Helfrich, A better TRAIL variant for tumor cell-specific targeting? - Letter. Mol. Cancer Ther. 9, 2853 (2010).
13. J. E. Allen, R. Ferrini, D. T. Dicker, G. Batzer, E. Chen, D. I. Oltean, B. Lin, M. W. Renshaw, A. Kretz-Rommel, W. S. El-Deiry, Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol. Cancer Ther. 11, 2087-2095 (2012).
14. L. G. Menon, K. Kelly, H. W. Yang, S. K. Kim, P. M. Black, R. S. Carroll, Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 27, 2320-2330 (2009).
15. K. Kuribayashi, G. Krigsfeld, W. Wang, J. Xu, P. A. Mayes, D. T. Dicker, G. S. Wu, W. S. El-Deiry, TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol. Ther. 7, 2034-2038 (2008).
16. S. Ghaffari, Z. Jagani, C. Kitidis, H. F. Lodish, R. Khosravi-Far, Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc. Natl. Acad. Sci. USA. 100, 6523-6528 (2003).
17. J. E. Allen, W. S. El-Deiry, Regulation of the human TRAIL gene. Cancer Biol. Ther. 13,1143-1151 (2012).
18. F. Bunz, P. M. Hwang, C. Torrance, T. Waldman, Y. Zhang, L. Dillehay, J. Williams, C. Lengauer, K. W. Kinzler, B. Vogelstein, Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269 (1999).
19. E. L. Greer, A. Brunet, FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410-7425 (2005).
20. J. Y. Yang, C. S. Zong, W. Xia, H. Yamaguchi, Q. Ding, X. Xie, J. Y. Lang, C. C. Lai, C. J. Chang, W. C. Huang, H. Huang, H. P. Kuo, D. F. Lee, L. Y. Li, H. C. Lien, X. Cheng, K. J. Chang, C. D. Hsiao, F. J. Tsai, C. H. Tsai, A. A. Sahin, W. J. Muller, G. B. Mills, D. Yu, G. N. Hortobagyi, M. C. Hung, ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat. Cell Biol. 10, 138-148 (2008).
21. T. F. Burns, W. S. El-Deiry, Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276, 37879-37886 (2001).
22. A. Ashkenazi, R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, R. H. Schwall, Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162 (1999).
23. V. Modur, R. Nagarajan, B. M. Evers, J. Milbrandt, FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J. Biol. Chem. 277, 47928-47937 (2002).
24. M. C. T. Hu, D. F. Lee, W. Xia, L. S. Golfman, F. Ou-Yang, J. Y. Yang, Y. Zou, S. Bao, N. Hanada, H. Saso, R. Kobayashi, M. C. Hung, IkB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237 (2004).
25. N. Finnberg, W. S. El-Deiry, Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: An effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol. Ther. 3, 614-616 (2004).
26. W. Wang, W. S. El-Deiry, Targeting FOXO kills two birds with one stone. Chem. Biol. 11, 16-18 (2004).
27. W. Yang, N. G. Dolloff, W. S. El-Deiry, ERK and MDM2 prey on FOXO3a. Nat. Cell Biol. 10, 125-126 (2008).
28. V. Desplat, A. Geneste, M. A. Begorre, S. B. Fabre, S. Brajot, S. Massip, D. Thiolat, D. Mossalayi, C. Jarry, J. Guillon, Synthesis of new pyrrolo[1,2-a]quinoxaline derivatives as potential inhibitors of Akt kinase. J. Enzyme Inhib. Med. Chem. 23, 648-658 (2008).
29. M. F. Favata, K. Y. Horiuchi, E. J. Manos, A. J. Daulerio, D. A. Stradley, W. S. Feeser, D. E. Van Dyk, W. J. Pitts, R. A. Earl, F. Hobbs, R. A. Copeland, R. L. Magolda, P. A. Scherle, J. M. Trzaskos, Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623-18632 (1998).
30. J. Y. Yang, C. J. Chang, W. Xia, Y. Wang, K. K. Wong, J. A. Engelman, Y. Du, M. Andreeff, G. N. Hortobagyi, M. C. Hung, Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res. 70, 4709-4718 (2010).
31. M. M. Shareef, N. Cui, R. Burikhanov, S. Gupta, S. Satishkumar, S. Shajahan, M. Mohiuddin, V. M. Rangnekar, M. M. Ahmed, Role of tumor necrosis factor-α and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res. 67, 11811-11820 (2007).
32. H. Walczak, R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T. Rauch, J. C. Schuh, D. H. Lynch, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157-163 (1999).
33. A. N. Cornforth, J. S. Davis, E. Khanifar, K. L. Nastiuk, J. J. Krolewski, FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene 27, 4422-4433 (2008).
34. S. J. Park, H. Y. Sohn, J. Yoon, S. I. Park, Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells. Cell. Signal. 21, 1495-1503 (2009).
35. T. R. Kau, F. Schroeder, S. Ramaswamy, C. L. Wojciechowski, J. J. Zhao, T. M. Roberts, J. Clardy, W. R. Sellers, P. A. Silver, A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4, 463-476 (2003).
36. H. Ebi, R. B. Corcoran, A. Singh, Z. Chen, Y. Song, E. Lifshits, D. P. Ryan, J. A. Meyerhardt, C. Benes, J. Settleman, K. K. Wong, L. C. Cantley, J. A. Engelman, Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest. 121, 4311-4321 (2011).
37. J. van Grevenynghe, R. A. Cubas, A. Noto, S. DaFonseca, Z. He, Y. Peretz, A. Filali-Mouhim, F. P. Dupuy, F. A. Procopio, N. Chomont, R. S. Balderas, E. A. Said, M. R. Boulassel, C. L. Tremblay, J. P. Routy, R. P. Sékaly, E. K. Haddad, Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J. Clin. Invest. 121, 3877-3888 (2011).
38. A. Nebbioso, N. Clarke, E. Voltz, E. Germain, C. Ambrosino, P. Bontempo, R. Alvarez, E. M. Schiavone, F. Ferrara, F. Bresciani, A. Weisz, A. R. de Lera, H. Gronemeyer, L. Altucci, Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11, 77-84 (2005).
39. J. Abdulghani, W. S. El-Deiry, TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets 14, 1091-1108 (2010).
40. S. H. Kim, K. Kim, J. G. Kwagh, D. T. Dicker, M. Herlyn, A. K. Rustgi, Y. Chen, W. S. El-Deiry, Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J. Biol. Chem. 279, 40044-40052 (2004).
41. W. Wang, S. H. Kim, W. S. El-Deiry, Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc. Natl. Acad. Sci. U.S.A. 103, 11003-11008 (2006).
42. S. Wang, W. S. El-Deiry, Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci. U.S.A. 100, 15095-15100 (2003).
43. T. Anastassiadis, S. W. Deacon, K. Devarajan, H. Ma, J. R. Peterson, Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045 (2011).
44. -ΔΔCT method. Methods 25, 402-408 (2001).